A review article published in February 2019 in the Annals of Pharmacology reviewed 241 articles including both full text and conference abstracts looking at the safety and effectiveness of capsaicin cream for treating marijuana hyperemesis syndrome.  Although there is little data, the article commented that capsaicin is recommended as a reasonable first-line treatment approach for CHS despite limited clinical evidence regarding its use and that capsaicin use was described as beneficial in all case series and case reports; however, both retrospective cohort studies were unable to find a significant benefit for capsaicin on primary outcomes (emergency department length of stay).  The article then concluded that although there is limited data on alternative antiemetic therapies but that capsaicin’s favorable risk-benefit profile make it a reasonable adjunctive treatment option.